Replies to post #200871 on Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Def would be on board w that idea
Partner and let someone else advance B-ABSSSI regionally, push ahead --

The article below is behind paywall but does place ABSSSI Ph3 at $30 to $50m; so v glad company spending $ to develop B in lower-hanging fruit (less costly indications) ---- OM, IBD.

--

The antibiotic pipeline: reviving research and development and speeding drugs to market.

"average cost of just Phase 3 development alone can range from $30-50 million (acute bacterial skin and skin structure infection, ABSSSI)"

http://www.tandfonline.com/doi/abs/10.1080/14787210.2017.1308251

Also came across ref to a recent 2017 DeGrado Keynote presentation....
One of the original Brains behind Brilacidin.

Link below.

Good to see he's still chatting up HDP-M Science.

--

William Degrado (University of California, San Francisco, USA)
"Design, Characterization and Mechanisms of Bacterial Response to Small Molecule Mimics of Antimicrobial Peptides"

https://www.grc.org/antimicrobial-peptides-conference/2017/

[baytdr]

As i mentioned once before I own another company that has partnered Japan only for stroke, as I suggest IPIX should do with ABSSSI, that other co. had a similar mkt cap about a year ago, it now has a MC approaching 3 times IPIX's, primarily due to that partnership. Partnering is the name of the game for public pre-revenue bio in this market climate, so why not partner in a foreign country with a regional player preserving the largest markets. Not so much for revenue but rather to off load the expense of advancing the pipeline.